PMID- 10495037
OWN - NLM
STAT- MEDLINE
DCOM- 19991110
LR  - 20191024
IS  - 0885-3185 (Print)
IS  - 0885-3185 (Linking)
VI  - 14
IP  - 5
DP  - 1999 Sep
TI  - Increased expression of dopamine receptors on lymphocytes in Parkinson's disease.
PG  - 764-71
AB  - Dopamine D1-like and D2-like receptors on peripheral blood lymphocytes (PBL) were
      assayed in 50 de novo patients with idiopathic Parkinson's disease (PD), in 36
      neurologic control subjects (multiple-system atrophy, n = 16; essential tremor, n
      = 10; other neurodegenerative diseases, n = 10), and in 26 healthy control
      subjects by radioligand binding assay techniques using [3H]SCH 23390 and
      [3H]7OH-DPAT as ligands. Patients with PD revealed a higher density (Bmax) of
      dopamine D1-like (p <0.001) and D2-like (p <0.00001) receptors on PBL than either
      neurologic or healthy control subjects, whereas no differences in Bmax were
      observed among patients affected by other neurologic diseases and healthy control
      subjects. The affinity (Kd) of both radioligands was similar in the groups
      investigated. The pharmacologic profile of [3H]SCH 23390 and [3H]7OH-DPAT binding
      was consistent with the labeling of dopamine D5 and D3 receptor subtypes,
      respectively. Twenty-five of the 50 patients with PD were retested after 3 months
      of therapy with levodopa or bromocriptine. Both treatments reduced the density of
      D1-like (p <0.001) and D2-like (p <0.001) receptors on PBL to values comparable
      to those of control subjects. The increased density of D1-like and D2-like
      receptors on PBL in de novo PD patients may represent an upregulation mechanism
      resulting from the diffuse impairment of the dopaminergic system in PD.
FAU - Barbanti, P
AU  - Barbanti P
AD  - Department of Neurosciences, University La Sapienza, Rome, Italy.
FAU - Fabbrini, G
AU  - Fabbrini G
FAU - Ricci, A
AU  - Ricci A
FAU - Cerbo, R
AU  - Cerbo R
FAU - Bronzetti, E
AU  - Bronzetti E
FAU - Caronti, B
AU  - Caronti B
FAU - Calderaro, C
AU  - Calderaro C
FAU - Felici, L
AU  - Felici L
FAU - Stocchi, F
AU  - Stocchi F
FAU - Meco, G
AU  - Meco G
FAU - Amenta, F
AU  - Amenta F
FAU - Lenzi, G L
AU  - Lenzi GL
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Mov Disord
JT  - Movement disorders : official journal of the Movement Disorder Society
JID - 8610688
RN  - 0 (Antiparkinson Agents)
RN  - 0 (Dopamine Agonists)
RN  - 0 (Receptors, Dopamine)
RN  - 46627O600J (Levodopa)
SB  - IM
MH  - Aged
MH  - Antiparkinson Agents/therapeutic use
MH  - Binding, Competitive/physiology
MH  - Brain/pathology
MH  - Cell Count
MH  - Dopamine Agonists/pharmacokinetics
MH  - Female
MH  - Humans
MH  - Levodopa/therapeutic use
MH  - Lymphocytes/*metabolism
MH  - Magnetic Resonance Imaging
MH  - Male
MH  - Middle Aged
MH  - Parkinson Disease/diagnosis/drug therapy/*metabolism
MH  - Radioligand Assay
MH  - Receptors, Dopamine/*metabolism
MH  - Sensitivity and Specificity
MH  - Treatment Outcome
EDAT- 1999/09/24 00:00
MHDA- 1999/09/24 00:01
CRDT- 1999/09/24 00:00
PHST- 1999/09/24 00:00 [pubmed]
PHST- 1999/09/24 00:01 [medline]
PHST- 1999/09/24 00:00 [entrez]
AID - 10.1002/1531-8257(199909)14:5<764::aid-mds1008>3.0.co;2-w [doi]
PST - ppublish
SO  - Mov Disord. 1999 Sep;14(5):764-71. doi:
      10.1002/1531-8257(199909)14:5<764::aid-mds1008>3.0.co;2-w.